García-Martínez J, Folgueira L, Delgado R, Hernando S, Prieto C, Aguado J M, Otero J R
Department of Microbiology, Madrid, Spain.
Transpl Infect Dis. 2008 Apr;10(2):123-8. doi: 10.1111/j.1399-3062.2007.00243.x. Epub 2007 Jul 1.
We reported a ganciclovir (GCV)-resistant cytomegalovirus (CMV) infection in a heart transplant recipient. Genotypic and phenotypic susceptibility assays demonstrated an A594V mutation in the UL97 phosphotransferase gene and GCV IC(50)>96 microM. Low GCV concentration exposure, immunosuppressive treatment, donor-positive/recipient-negative CMV serostatus, viral reactivations within antiviral prophylaxis or treatment, contributed to GCV-resistant strain selection.
我们报告了1例心脏移植受者中出现的耐更昔洛韦(GCV)的巨细胞病毒(CMV)感染。基因型和表型药敏试验显示,UL97磷酸转移酶基因存在A594V突变,且更昔洛韦的半数抑制浓度(IC50)>96 μM。低浓度更昔洛韦暴露、免疫抑制治疗、供体CMV血清学阳性/受体CMV血清学阴性状态、抗病毒预防或治疗期间的病毒再激活,均促使了耐更昔洛韦毒株的选择。